Fig. 8: LAPTM5 is specifically activated in lung metastases of multiple cancers.
a Double clustering heatmap of top 20 up- and down-regulated genes in breast cancer (BCa) cells with lung metastatic activity (Lung-M, n = 5 cell lines) compared with populations with mediate activity (Mediate, n = 11 cell lines) and bone metastatic activity (Bone-M, n = 5 cell lines) in the GSE1206 dataset. b LAPTM5 counts in BCa cells with mediate (Mediate, n = 11), lung metastatic (Lung-M, n = 5) and bone metastatic (Bone-M, n = 5) activity in the GSE1206 dataset. c LAPTM5 expression in brain (n = 27 samples), lung (n = 4 samples), liver (n = 2 samples), bone (n = 1 sample), other organs (n = 9 samples) and lymph node (n = 9 samples) metastases from melanoma in the GSE50496 dataset. d LAPTM5 expression in primary tumors (n = 186 samples), lung (n = 20 samples) and liver (n = 47 samples) metastases from colorectal cancer in the GSE41258 dataset. e IB analysis of control and Laptm5-overexpressing or control and Laptm5-silenced 4T1luci cells. Immunoblots are representative of three biological replicates. f Schematic illustration for the mammary pad cell inoculation, in situ tumor measurement and lung metastases detection using the murine 4T1 breast cancer cell line. g Tumor volumes of control and Laptm5-silenced 4T1luci cells inoculated in situ as described in (f). n = 10 mice per group. The data represent the mean ± SEM. h Representative IHC images of luciferase staining in lung sections harvested from mice treated as in (f). Scale bar, 50 μm. i Quantification of metastases per lung section at 24 days after mammary pad injection in each group (n = 5 mice per group). In b, c, d, and i, the data are presented as whisker plots: midline, median; box, 25–75th percentile; whisker, minimum to maximum values. Two-tailed Student’s unpaired t-test was used for statistical analysis in all panels. Source data are provided as a Source data file.
